TLV has decided to reconsider the subsidy for Olumiant


14 January 2020 - When TLV decided that Olumiant should be included in the high-cost protection, this was justified by the fact that the cost of use was lower than the TNF inhibitor comparison option. 

Since then, the cost of TNF inhibitors has decreased, which means that the cost of using Olumiant today is higher than for most TNF inhibitors. 

TLV therefore finds reasons to review the decisions with a view to reviewing the current subsidy limitation.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder